Los Angeles Capital Management LLC raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 213.6% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 1,440,384 shares of the company's stock after buying an additional 981,083 shares during the period. Johnson & Johnson comprises approximately 1.1% of Los Angeles Capital Management LLC's holdings, making the stock its 19th largest holding. Los Angeles Capital Management LLC owned about 0.06% of Johnson & Johnson worth $238,873,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in JNJ. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson during the 4th quarter worth about $29,000. Conquis Financial LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $33,000. Bernard Wealth Management Corp. bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.
Analyst Upgrades and Downgrades
JNJ has been the subject of several research reports. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Raymond James Financial decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. UBS Group reiterated a "buy" rating and set a $190.00 price target (up previously from $180.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $172.87.
View Our Latest Report on JNJ
Johnson & Johnson Trading Up 2.2%
Shares of NYSE:JNJ traded up $3.54 on Tuesday, hitting $167.90. The company had a trading volume of 9,277,637 shares, compared to its average volume of 8,146,115. The firm's 50-day simple moving average is $154.29 and its two-hundred day simple moving average is $155.12. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $403.99 billion, a price-to-earnings ratio of 17.96, a P/E/G ratio of 2.08 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.82 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.10%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
